<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04384991</url>
  </required_header>
  <id_info>
    <org_study_id>HU-007_P3-1</org_study_id>
    <nct_id>NCT04384991</nct_id>
  </id_info>
  <brief_title>HU007 Eye Drops in Patients With Dry Eye Syndrome</brief_title>
  <official_title>A Multicenter, Randomized, Double Blind, Restasis-controlled Non-inferiority, Phase III Study to Evaluate the Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huons Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huons Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, randomized, double blind, Restasis-controlled non-inferiority,
      Phase III Study to evaluate the efficacy and safety of HU007 eye drops in patients With dry
      eye syndrome
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 3, 2019</start_date>
  <completion_date type="Actual">December 5, 2019</completion_date>
  <primary_completion_date type="Actual">December 5, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in corneal staining score-Oxford grading</measure>
    <time_frame>Week 12</time_frame>
    <description>Change from baseline in corneal staining score-Oxford grading at Week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in corneal staining score-Oxford grading</measure>
    <time_frame>Week 4, 8</time_frame>
    <description>Change from baseline in corneal staining score-Oxford grading at Week 4, 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in conjunctival staining score-Oxford grading</measure>
    <time_frame>Week 4, 8, 12</time_frame>
    <description>Change from baseline in conjunctival staining score-Oxford grading at Week 4, 8, 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in strip meniscometry</measure>
    <time_frame>Week 4, 8, 12</time_frame>
    <description>Change from baseline in strip meniscometry at Week 4, 8, 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Tear film break-up time</measure>
    <time_frame>at Week 4, 8, 12</time_frame>
    <description>Change from baseline in Tear film break-up time at Week 4, 8, 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline of Standard patient evaluation of eye dryness questionnaire</measure>
    <time_frame>at Week 4, 8, 12</time_frame>
    <description>Change from Baseline of Standard patient evaluation of eye dryness questionnaire at Week 4, 8, 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve 100% clearance on the corneal staining score</measure>
    <time_frame>upto week 12</time_frame>
    <description>Time to achieve 100% clearance on the corneal staining score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">216</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>HU007 Eye drop</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adminster twice a day(one drop would be administered to both eyes once a time). When being administered, the IP should be mixed by upside down.
Medication is recommended at 9AM(±1H) and 9PM(±1H)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restasis Eye drop 0.05% (Cyclosporine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adminster twice a day(one drop would be administered to both eyes once a time). When being administered, the IP should be mixed by upside down.
Medication is recommended at 9AM(±1H) and 9PM(±1H)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HU007</intervention_name>
    <description>Cyclosporine 0.02% with Trehalose 3%</description>
    <arm_group_label>HU007 Eye drop</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Restasis eye drop</intervention_name>
    <description>Cyclosporine 0.05%</description>
    <arm_group_label>Restasis Eye drop 0.05% (Cyclosporine)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and Female who over 19 years old

          -  Those who meet below criteria at least one of two eyes

               1. Those who have over than score 2 in corneal staining test-Oxford grading

               2. Tear secretion test without anesthesia(Schirmer test) result would be under
                  10mm/5min (If the test result is 0mm/5min, it should be over than 3mm/5min on the
                  nasal stimulation schirmer test in the same eye)

               3. TBUT(Tear film break-up time) test result should be under 10sec.

          -  Woman with no possibility of pregnancy or negative pregnancy test results at a
             screening visit, Women or men who have agreed to maintain at least one contraceptive
             method during study period

          -  Those who could understand this study and agree to informed consent voluntarily

        Exclusion Criteria:

          -  Those who have clinically significant eye disease not related to dry eye symdrome

          -  Those who are in anti-inflammatory medication for dry eye syndrome

          -  Medication of systemic steroid or immunosuppressant

          -  Those who have worn contact lenses before 72hours or have to wear contact lenses or
             disagree not to wear contact lenses during study period

          -  Those who have medical history with intraocular surgery 90 days before screening visit

          -  Those who have any active ophthalmic diseases such as active allergy, anterior
             uveitis, stevens-johnson syndrom which could affect the surfece of eye

          -  Those who have any autoimmune diseases

          -  Those who need a surgery for surface elevation caused by meibomian gland
             dysfunction(MGD)

          -  Those who have any medical history of corneal transplantation or neurotrophic
             keratitis

          -  Those who have diagnosed with glaucoma or have an intraocular pressure over than
             25mmHg at least in one of the eyes

          -  Those who have medicated cyclosporine or steroid eye-drops 30 days before screening
             visit

          -  Those who have underwent any eye correction surgery such as LASIK(Laser-assistant in
             situ keratomileusis) 12 months before screening visit

          -  Those who have underwent a silicone lacrimal punctal occlusion or cauterization of the
             punctum excluding collagen lacrimal punctal occlusion 90 days before screening visit

          -  Those who have a hypersensitivity reaction for cyclosporine, trehalose or
             protein-based medication related to investigational drug

          -  Those who have diagnosed a psychical disorder which could affect this study

          -  Women who is pregnant or breastfeeding or those who have a plan to be pregnant

          -  Those who have medical history on abusing medications or alchol

          -  Those who have received other investigational drugs/devices 30 days before screening
             visit

          -  Those who are inappropriate for participating in this study according to
             investigator's judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD would be substituted for screening or random No.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

